

Effects of Oral Contraceptives on Blood Coagulation: Coagulation and Fibrinolysis A Review

Fritz K. Beller, and Christa Ebert

Frauenklinik der Westfälischen, Wilhelms-Universität Münster/Westfalen, West Germany

Introduction

Reports on the association between thromboembolic complications and the ingestion of oral contraceptives resulted in large numbers of studies concerning the effect of estrogens and progestagens on coagulation and the fibrinolytic enzyme system. The data simulated the physiologic increase of coagulation factors in pregnancy. It was therefore assumed that in both instances of human pregnancy and pill users, the estrogen was responsible for such an increase. In turn this would explain the higher incidence of thromboembolic complications during the ingestion of oral contraceptives. Mammen (114) recently pointed out that this concept is not that simple for the confusion. This refers to the concept of a hypercoagulable state, postulated to be a pre-thrombotic or thrombophilic state, hypothetic at best since at present no test system can predict a thromboembolic event. Furthermore, coagulation changes *in vitro* were interpreted as being reflective of a thromboembolic event *in vivo*. Finally, investigators using retrospective and prospective epidemiologic data, claimed a cause:effect relationship without considering physiologic principles.

A review of the data in the literature revealed large variations of study design and results. Many coagulation tests were used and appear not to be very well standardized. Thus, methodical errors were frequently observed.

The physiologic changes of the coagulation system in pregnancy were recently reviewed (24). The present paper is concerned with a review of the changes of the coagulation system during the menstrual cycle.

and fibrinolytic enzyme system in patients taking oral contraceptives. Since the data of this as well as that of our previous review on the physiology of pregnancy are evaluated in a similar fashion results may be deemed comparable.

Parameter of Coagulation and Fibrinolysis during the normal cycle

The few studies on the coagulation and fibrinolytic enzyme system, performed during the normal ovulatory cycle revealed conflicting data. During menstruation the recalcification time was decreased in one study (41). Other investigators found the results of this test to be normal. Older data failed to show changes of the prothrombin time. The plasma fibrinogen concentration was found to be unchanged (20); others found a peak increase during ovulation and 4 to 5 days before menstruation (172). Fibrinolysis was increased during menstruation but fibrinogen breakdown products remained unchanged. Beller et al. (21) found no change of fibrinolytic components in peripheral plasma during the menstrual cycle. Inhibitors, especially α_2 -antiplasmin and α_2 -macroglobulin revealed a tendency to somewhat increased values during the secretory phase, during the secretory phase but this was not statistically significant (176). The only significant change was which increased toward ovulation time and decreased during the secretory phase (64, 92, 141, 144). The peak increase of the platelet number predictable was to such a degree that it was used some 20 years ago for prediction of ovulation (130).

The unaltered system indicates that cycle-induced changes can be disregarded. Variables during the ingestion of sex steroids must therefore be attributed to the pill.

Reprint requests to: Prof. Fritz K. Beller, M.D., Frauenklinik der Westfälischen, Wilhelms Universität, Albert Schweitzerstr 33, 4400 Münster-Westfalen, West Germany.

The Effect of Estrogen and Progestogen on the Coagulation and Fibrinolytic Enzyme System

Fibrinogen concentration

Clotting Tests

A number of studies indicated a shortened clotting time (thrombelastogram, recalcification time or similar methods). However, since the test systems were not standardized, none allow the conclusion of a hypercoagulable state.

Platelet Number and Vessel Wall Interaction during Oral Contraceptives

Platelet aggregation was found to be less inhibited in females using the pill (26, 58, 75, 118, 125), but there were conflicting results (82, 151, 162). The same is true for platelet adhesion which some researchers found increased (7, 40, 58, 133) while others observed normal control values (13, 75, 108, 125, 171). An increase of platelet release reaction, especially of platelet factor IV, was noted.

With a few exceptions the platelet number was found unaltered by most authors (7, 12, 82, 98, 108, 133, 157, 162). An increase in the secretion profile together with an increased volume of platelet granules, reduced the number in mitochondria. A decreased volume and surface of the open canicular system and an increased surface of the dense tubular system were noted in morphologic studies of long-term pill users (1).

Activation phase. Only one study is available on the concentration of factor XI (53). Factor XII concentration seems to be unaltered and this is also true for the few studies regarding factor XIII (2, 17, 158).

Factor I (plasma fibrinogen concentration). A uniform reaction was noted regarding plasma fibrinogen. Increased concentration was found in nearly all studies (Table 1). This increase was clearly dose dependent (21, 107, 166). One study noted no change when a pill with 30 µg estriol was used while an increase of 11 per cent was noted in another study (121).

Intrinsic system. With just one exception (99) a slight increase in the concentration of plasma prothrombin, as determined by using one-phase or two-phase methods, was noted by the majority of authors (9, 21, 36, 50, 83, 107, 118, 121, 171). An increased thrombin formation was also noted (95). Most authors found an increase in factor VII (Table

Hormone	Effect (%)	Reference No.
Estrogen		
50 µg ethynylestradiol or 100 µg norethindrone	9	2
50-100 µg estrogen	13	17
50 µg estrogen	13	171
2.5 mg piperazine estrone sulfate		107
		13
Estrogen + progestogen		
20 µg norethindrone		2
50 µg Ethynylestradiol + 4 mg Norethisterone		
100 µg mestranol + 5 mg megestrol acetate	Significant	6
50 µg Ethynylestradiol + 30 µg Ethynylestradiol	15	121
30 µg Ethynylestradiol + 50 µg Ethynylestradiol + 1 mg norethisterone	11	
50 µg Ethynylestradiol + 3-4 mg Norethisterone	21	
50 µg Ethynylestradiol + 0.5 mg Ethynylacetate + Mestranol + norethynodrel	20	107
100 µg mestranol + 5 mg megestrol acetate	6	166
75 µg estranol + 5 mg Estrogen + progestagen		115
Ethynylestradiol + Quingestrone acetate		9
50 µg Ethynylestradiol + 150 µg Levonorgestrel		31
50 µg Ethynylestradiol + 1 mg Norethindrone acetate	Significant (1 week)	14
30 µg ethynylestradiol + 0.15 mg n-norgestrel	Significant	98
50 µg Ethynylestradiol + 1 mg Norethindrone		
30 µg ethynylestradiol + 0.15 mg n-norgestrel		182
50 µg Ethynylestradiol + 1 mg Norethindrone		4
35 µg Ethynylestradiol + 400 µg norethindrone		
Progestogen		
5 mg norethynodrel		53
1 mg norethindrone		150

2). Factor X, a factor closely related to factor VII, revealed as expected similar data (Table 3).

Factor V. In the very few studies available an increase was noted (50, 115, 118, 129) but most results indicated unchanged results even after ingestion of very high doses of the pill (7, 32, 82, 101, 133, 153, 157).

TABLE 4. Factor VII concentration. TABLE 5. Factor VIII concentration. TABLE 6. Factor IX concentration. TABLE 7. Factor X concentration.

Reference	Hormone	Effect (%)	Reference No.
Estrogen			
107	2.5 mg piperazine estrone sulfate	107	
	50 µg ethynylestradiol	45	
	30 µg ethynylestradiol	16	
Estrogen + Progestogen			
149	50 µg ethynylestradiol + 1 mg norethisterone	66	
150	50 µg ethynylestradiol + 3-4 mg norethisterone		
121	7.5 µg mestranol		157
	5 mg norethynodrel		
	50 µg ethynylestradiol	60	107
	1 mg norethindrone		
	Norethynodrel + mestranol	31-48	115
	100 µg mestranol	27	83
	2 mg norethindrone	8	21
	150 µg mestranol		
	9.85 mg norethynodrel		
	100 µg mestranol + norethisterone (2 mg)	Significant	9
	100 µg mestranol + 5 mg megestrol	Significant	6
	Ethynylestradiol + Norethindrone acetate	Significant	34
	0.25 mg D-Norgestrel + 50 µg Ethynylestradiol		
Progestogen			
	Norethisterone	10	153

Reference	Hormones	Effect (%)	Reference No.
Estrogen			
	2.5 mg piperazine estrone sulfate		
Estrogen + progestogen			
	100 µg mestranol + 2 mg norethindrone	17	83
42	100 µg mestranol + 2 mg norethisterone		
	50 µg estrogen or 30 µg estrogen	26	
	Ethynylestradiol + norethindrone acetate	Significant	6
	45 µg Ethynylestradiol + 0.5 mg norethindrone	Significant	7
	30 µg Ethynylestradiol		180
	0.15 mg D-norgestrel		
Progestogen			
	40 µg Megestrol acetate (implant)		108
	Norethisterone		153

Factor VIII. In one of the first papers regarding coagulation changes under the pill (53) an increase was noted. This was confirmed by some authors (7, 98, 108, 115, 133) but others found a decrease or normal concentration (48, 50, 82, 83, 99, 114). The problem of unstandardized methods was obvious in this regard. On the basis of newer studies it is assumed that factor VIII is, indeed, increased.

Fibrinolytic system. Most investigators observed an increase in the concentration of plasminogen (Table 4). However, it is not clear whether this indicates an increased production rate or decreased consumption. Looking at data of test systems for fibrinolytic activity a number of investigators observed an increased (13, 17, 31, 80, 98, 166), and others noted no changed activity (86, 124). The activator concentration in the vessel wall was unchanged (133), whereas urokinase was found to be increased (13).

Antiplasmin activity was found to be normal, decreased (129), or increased (6, 86). In one case an increase of inhibitors against urokinase was noted

(133, 182), but in another instance a decrease (13, 17) was noted. Fibrinogen breakdown products were noted to be present in small quantities (13) which would mean an increase when compared to normal. In most studies there were no fibrin(ogen) breakdown products demonstrated in the circulation.

One author found an increase after termination of pregnancy. Mink et al. (129) stated that estrogens have a more distinct effect on the fibrinolytic effect than progestogens.

Antithrombin III (AT III) alpha one antithrombin (α_1 AT) and alpha 2 macroglobulin (α_2 MG). AT III activity decreases shortly after the ingestion of oral contraceptives (95). The effect was dose dependent and not observed after progestogen intake. The data are summarized in Table 4. Newer data using a dose of 30 µg of ethynyl estradiol revealed no significant change. There is agreement that α_1 AT increased as a result of estrogens (2, 11, 81, 98, 103). An increase of α_2 MG of the acute-phase protein α_1 AT was less significant described by the same authors.

Effects of Biphasic and Triphasic Oral Contraceptives

Most studies on the coagulation system were performed on patients taking the fixed combination of estrogens and progestogens. The sequential regimen was rarely examined, where estrogens for a period of 6 to 10 days were followed by a fixed dose of estrogens and progestogens (179). Only two stud-

TABLE 4 Plasmafibrinogen concentration

No.	Reference	Effect (%)	Hormone, No.
Estrogen			
Mestranol	171		
Ethinylestradiol			
17- β -estradiol	13	↑	
or ethinylestradiol			
50 μ g estrogen	23	↑	171
50 μ g ethinylestradiol or	13	↑	171
100 μ g mestranol			
2.5 mg piperazine es-	5	↑	107
trone sulfate			
Estrogen + Progestogen			
150 μ g mestranol + 9.85	42	↑	21
mg norethindrel			
100 μ g mestranol + 5	68	↑	82
mg megestrol			
Mestranol + megestrol	47	↑	103
60 μ g mestranol + nore-	20-60	↑	132
thindrel			
75 μ g mestranol + 5 mg	31	↑	31
norethindrel			
Estrogen + progestagen	40-60	↑	11
100 μ g mestranol + 0.5	24-30	↑	166
mg ethinylestradiol + quin-			
estrol acetate			
Ethinylestradiol + nore-	Significant	↑	6
thindrone acetate			
Ethinylestradiol + quin-			
gestanol acetate			
35 μ g ethinylestradiol +		↑	136
400 μ g norethindrone			
50 μ g estrogen + pro-	38	↑	176
gestogen			
Progestogen			
5 mg Norethindrone	5	↑	142
or			
5 mg norethisterone	5	↑	142
1 mg Norethisterone	Significant	↑	142
acetate			

TABLE 5 Amnionrombin in

Effect (%)	Hormone No.	Reference	Effect (%)
Estrogen			
50 μ g ethinylestradiol	8	↓	121
30 μ g ethinylestradiol	5		
50 μ g ethinylestradiol or	6.5	↓	2
100 μ g mestranol			
80 μ g mestranol or 1.25	28	↓	95
12 mg Premarin	15		
50 μ g Ethinylestradiol	8.5	↓	52
Mestranol or ethinyles-	12	↓	17
tradiol			
50 μ g estrogen	11	↓	171
17- β -estradiol		↓	13
20-35 μ g Ethinylestra-	Significant	↓	116
diol or 50 μ g mes-			
tranol			
2.5 mg Piperazine es-			107
trone sulfate			
Estrogen + Progestogen			
Estrogen + progestogen		↓	86
Estrogen + progestogen		↓	14
Estrogen + progestogen	9 (activity)	↓	14
	0 (immunol.)		
50 μ g ethinylestradiol +			
100 μ g gestranol acetate			
50-100 μ g mestranol +			80
10-12 mg norethindrone			
30 μ g ethinylestradiol			182
0.15 mg D-norgestrel			
50 μ g Ethinylestradiol +	28	↓	30
0.075 mg D-norgestrel			
0.5 mg lynestrenol	31		
50 μ g ethinylestradiol +			
400 μ g norethindrone			

Long-time related effects and Time Related

After 9 months Ambrus et al. (4) found various changes in the coagulation system which were not present after 2 years. In one study there was a significant increase of plasma fibrinogen as well as of the factors VII and VIII after 9 months of intake of 30 μ g of ethinyl estradiol and 1 mg of norethindrone. Plasma fibrinogen concentration remained high up to 24 months; factor X had, however, returned to normal values at 1 year (3). When 50 μ g of mestranol was used combined with 1 mg of norethindrone concentrate there was an increase after a 3-month intake for factors I, II, and VII which persisted for 6 months (128). No change was found when 0.5 mg of chlormadinone acetate was used.

In another study using 30 μ g of ethinyl estradiol and 0.15 mg of D-norgestrel during a 12-month period there was normalization of platelets, but the plasma thromboplastin time and the fibrinogen breakdown products remained

ies concerned the newer biphasic or triphasic oral contraceptives. Some differences were found between the first, second and the sixth treatment were compared against the pretreatment cycle. It is difficult to explain why an increase of plasma fibrinogen concentration was noted under the triphasic formulation but found lacking under the biphasic pill. The coagulation factors most strongly affected were factor VIII, von Willebrand's factor and factor VIII reactive protein. However, it should be noted that even within the framework of statistical changes these occurred in the normal range (33, 179). In another study an increase was noted in plasma fibrinogen concentration, factor VII, factor VIII, and factor X. The intake of the biphasic preparation showed the highest increase.

Estrogens in Menopause

The first study of the effect of estrogen in menopause was performed under administration of 30 mg of mestanol daily. There was an increase of plasma fibrinogen concentration and α_2 AT with a decrease of activated plasminogen and AT III at 1 year. Fibrinogen breakdown products were not increased (22). When 1.25 mg of Premarin was used, factor VII and

X were increased (43) and AT III was decreased (167).

Nonsteroidal estrogen preparation did not induce changes in factor II, VII, VIII, X, AT III and α_2 AT (99). There was only a slow decrease of AT III and an increase of α_2 AT and factor VII but no change of factors VIII and IX during the intake of estradiol valerate and estriol (66).

Largelius et al. (101) confirmed previous assump-




Fig. 1. Change of coagulation factors during pregnancy semischematic (used with permission from Ref. 1).

that so-called natural estrogens produce smaller effects than synthesized ones.

When Premarin (0.625 or 1.25 mg) was used together with medroxyprogesterone acetate there was no effect on coagulation system.

Some authors feel that postmenopausal women are less prone to thrombotic complications than women in the reproductive age. But this assumption has to be clarified by studies with larger populations.

Estrogens above the dosage levels of 0.5 μ g of ethinyl estradiol have an effect on the coagulation fibrinolytic enzyme system. Nearly all studies noted an increase in the plasma fibrinogen concentration, factor II (prothrombin), VII, VIII of the activation phase are not influenced. The same is true for platelet number, whereas platelet function is controversial. There is obviously overstimulation of the

	Decrease	Normal Range	Increase	
Plasma Fibrinogen I				COAGULATION
Fibrinogen Monomer				
Fibrinogen Monomer Complex				
Fibrin(ogen) Split Product				
Prothrombin (II)				
Factor V				
Factor VII				
Factor VIII				
F VIII Related Antigen				PREGNANCY
Factor IX				
Factor X				
Factor XI				
Factor XII				
Factor XIII				FIBINOLYSIS
Antithrombin III				
d1 Tissue Inhibitor				
d1 Macroglobulin				
Plasminogen				
Activator				Platelets
Platelet Number				
Platelet Function				

Fig. 2. Change of coagulation factors during ingestion of oral contraceptives.

tivity of the fibrinolytic enzyme system, predominantly related to activator activity. The effects are questionable in users of pills with an estrogen content of 0.3 μg of ethynylestradiol. There is little difference between monophasic, diaphasic, or triphasic preparations. There are no signs of induction of intravascular coagulation as the result of intake of the pill as judged by the lack of gamma-gamma dimers or free peptides a and b in the circulation. The existence of a hypercoagulable state is hypothetical at best. In this respect it is questionable as to whether the increase in concentration of coagulation factors can explain thromboembolic events associated with the use of oral contraception. Data to correlate the estrogen effect with smoking and age are lacking. If estrogens were such strong promoters of thromboembolic complications, many more women should be expected to become diseased since nearly all subjects demonstrated the effect with the higher doses. To explain thromboembolic events by the increase of coagulation factors is an unwarranted analogous conclusion.

Same data indicate that the increased coagulation factors return after months of normal use, although the individuals continue to take the pill. Data from estrogens alone, as well as from their use in the menopause, indicate that ethynylestradiol and mestranol are the steroids responsible for the coagulation effect. The so-called natural estrogens are effective only in high doses (1.25 mg), and nonsteroidal estrogens were inert. Presently the data available do not allow the conclusion that low dose progesterone has any effect on the coagulation system. This seems also to apply for the thromboembolic events. It should be considered therefore whether low dose progestogens can be used for patients with a history of thromboembolic disease.

In comparing the effects of oral contraception on coagulation and the fibrinolytic enzyme system with similar, physiological effects in pregnancy the concept was that in both instances the estrogens are responsible (Figs. 1 and 2). However, there are a number of obstacles against this concept. The increase in coagulation factors was not inducible in animals (138). When functional tests were used, i.e., activation of disseminated intravascular coagulation by endotoxin, disseminated intravascular coagulation was more pronounced in the gravid animal after a given dose than the nonpregnant animal prepared by estrogens and progestogen (23, 103). In humans thromboembolic complications in the puerperium are 10 times more frequent than in pregnancy. Therefore

it occurs at a time when coagulation factors return or have already returned to normal (24). Induced to normal remains to be seen to what extent thromboembolic complications will be reduced in users of pills containing 0.3 μg or less of ethynylestradiol.

The estrogen-induced change of coagulation factors is an interesting experimental model but its clinical significance is not yet clear.

Summary

A review of the data from studies of oral contraceptives on coagulation and the fibrinolytic enzyme systems reveal an increase of a variety of coagulation factors. This is dose dependent and related to estrogens and appreciable above a dose of 0.5 μg of ethynylestradiol. Smaller amounts are less effective or not at all active. The mechanism of this increase is unknown. The pathophysiological significance is not yet clear. There is no available data that associate the increase of coagulation factors with disseminated intravascular coagulation. Conclusive evidence that low dose progesterone has any effect on the coagulation system is lacking.

REFERENCES

1. Adams, J. H., Mitchell, J. R. A., and Sopitt, G. D.: Effect of oral contraceptives on lipoprotein activity and platelet stickiness. *Lancet* 2: 233, 1920.
2. Alkjaersig, N., Fletcher, A., and Burstein, R.: Association between oral contraceptive use and thromboembolism: A new approach to its investigation based on plasma fibrinogen chromatography. *Am. J. Obstet. Gynecol.* 122: 199, 1975.
3. Ambrus, J. L., Mink, J. B., Courey, N. G., et al.: Thromboembolic complications of oral contraceptive therapy. *Res. Commun. Chem. Pathol. Pharmacol.* 10: 197, 1975.
4. Ambrus, J. L., Niswander, K. R., Courey, N. G., et al.: Progestational agents and blood coagulation. *Am. J. Obstet. Gynecol.* 103: 994, 1969.
5. Ambrus, J. L., Niswander, K. R., Courey, N. G., et al.: Progestational agents and blood coagulation. *Progestational agents and blood coagulation cycle effects.* *J. Reprod. Med.* 6: 37, 1971.
6. Ambrus, J. L., Mink, J. B., and Courey, N. G.: Progestational agents and blood coagulation VII. Thromboembolic and other complications of oral contraceptive therapy in relation to pretreatment levels of blood coagulation factors. Summary report of a ten year study. *Am. J. Obstet. Gynecol.* 125: 1057, 1976.
7. Ambrus, J. L., Courey, N. G., Browne, B. J., et al.: Progestational agents and blood coagulation VIII. Effect of low-dose alternate-day, estrogen-progestin combinations in blood coagulation factors in man with a special note on the effect of freezing of blood samples. *Am. J. Obstet. Gynecol.* 128: 161, 1977.
8. Ambrus, J. L., Courey, N. G., and Ambrus, M. S.: Effect of oral contraceptives on the serum-induced thrombosis phenomenon. *Proc. Natl. Acad. Sci. U.S.A.* 62: 150, 1969.
9. Amris, C. J., and Starup, J.: The coagulation mechanism in oral contraception. *Acta Obstet. Gynecol. Scand.* 46: 78, 1967.

10. Amundson, B. A., and Pilgermann, L. O.: Observations on a relationship between steroid metabolism and the concentration of plasma fibrinogen. *Thromb. Diath. Haemorrh.* 10: 400, 1963.
11. Asbeck, F., Lechler, E., van de Loo, J.: Das Verhalten des fibrinolytischen Systems unter Östrogen-Gestagen Kombinationen. In *Sexualhormone und Blutgerinnung. XIV. Homberger Symposium über Blutgerinnung*. Schattauer, Verlag, Stuttgart-New York, 1971, pp. 133.
12. Astedt, B., and Jeppsson, S.: Thromboembolism and oral contraceptives. *Br. Med. J.* 2: 333, 1974.
13. Astedt, B.: Coagulation and fibrinolytic studies on 17- β -Estradiol and synthetic estrogens. *Acta Obstet. Gynecol. Scand. (suppl.)* 65: 45, 1976.
14. Astedt, B., Isacson, S., Nilsson, J. M., and Pandolfi, M.: Thrombosis and oral contraceptives: Possible predisposition. *Br. Med. J.* 4: 631, 1973.
15. Astedt, B.: Fibrinolytic activity of vein walls during treatment with ethinylloestradiol. *Acta Obstet. Gynecol. Scand.* 50: 279, 1971.
16. Astedt, B.: Low fibrinolytic activity of veins during treatment with ethinylloestradiol. *Acta Obstet. Gynecol. Scand.* 50: 279, 1971.
17. Ball, A. P., and McKee, P. A.: Fibrin formation and dissolution in women receiving oral contraceptive drugs. *Br. Med. J.* 1: 74, 1970.
18. Basu, H. K.: Fibrin degradation products in sera of women with normal menstruation and menorrhagia. *Br. Med. J.* 1: 74, 1970.
19. Beller, F. K.: Pathophysiologic aspects of circulating endotoxin in septic abortion. *Int. J. Gynaecol. Obstet.* 8: 617, 1970.
20. Beller, F. K., Goebelsman, U., Douglas, G. W., and Johnson, A. J.: The fibrinolytic system during menstrual cycle. *Obstet. Gynecol.* 23: 12, 1964.
21. Beller, F. K., and Porges, R. F.: Blood coagulation and fibrinolytic enzyme studies during cyclic and continuous application of progestational agents. *Am. J. Obstet. Gynecol.* 97: 448, 1967.
22. Beller, F. K., Naciri, L., and Rosenberg, M.: Coagulation studies of menopausal women taking estrogen replacement. *Obstet. Gynecol.* 39: 775, 1972.
23. Beller, F. K., and Schoendorf, T.: Augmentation of endotoxin induced fibrin deposits by pregnancy and estrogen-progesterone treatment. *Gynecol. Invest.* 3: 176, 1972.
24. Beller, F. K., and Ebert, C. H.: The coagulation and fibrinolytic system in pregnancy and in the puerperium. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 13: 171, 1982.
25. Bergqvist, A., Bergqvist, D., and Hedner, U.: Oral contraceptives and venous thromboembolism. *Br. J. Obstet. Gynecol.* 89: 381, 1982.
26. Bierenbaum, M. L., Fleischman, A. I., Stier, A., et al.: Intravascular platelet aggregation and increased platelet aggregation in women on oral contraceptives. *Am. J. Obstet. Gynecol.* 134: 638, 1979.
27. Bloom, A. L., Beck, P., Giddings, J. C., and Sweetnam, P. M.: Coagulation studies in haemophilic patients taking oral contraceptives. *J. Clin. Pathol.* 24: 23, 1971.
28. Böttiger, L. E., Boman, G., Eklund, G., and Westerholm, B.: Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. *Lancet* 1: 1442, 1975.
29. Bonnar, J., Haddon, M., Hunter, D. H., et al.: Coagulation system changes in post-menopausal women receiving oestrogen preparations. *Postgrad. Med. J.* 52: (suppl 6) 30, 1976.
30. Bourgeois, H., Dublet, F., Wille, J., et al.: The determination of antithrombin III. Comparison of the methods. Effect of oral contraceptive therapy. *Thromb. Haemostas.* 39: 607, 1978.
31. Brakman, P., Sobrero, A. J., and Astrup, T.: Effect of different systemic contraceptives on blood fibrin lysis. *Am. J. Obstet. Gynecol.* 106: 187, 1970.
32. Brakman, P., Albrechtsen, O. K., and Astrup, T.: Blood coagulation, fibrinolysis and contraceptive. *Acta Obstet. Gynecol.* 199: 69, 1967.
33. Brandt, M., Hofmann, K. D., and Koob, P.: Die Beeinflussung des fibrinstabilisierenden Faktors (Factor XIII) durch hormonale Kontrazeptiva. *Zentralbl. Gynäkol.* 102: 353, 1980.
34. Briggs, M. H.: Thromboembolism and oral contraceptives. *Br. Med. J.* 1: 503, 1974.
35. Briggs, M. H.: Comparative investigation of oral contraceptives using randomized prospective controls. In *Benefits and Risks of Oral Contraception*, edited by A. A. Haspel, and R. Rolland. MTP Press, Lancaster, 1982.
36. Brodsky, J., Lewis, G., and Ross, E.: Effect of pregnancy or a progestational drug on blood coagulation as measured by the thromboplastin time. *Am. J. Obstet. Gynecol.* 113: 100, 1972.
37. Cafferata, H. T., Robinson, A. J., Adgeler, P. M., and Blaisdell, F. W.: Intravascular coagulation in the surgical patient. *Am. J. Surg.* 118: 281, 1969.
38. Caprini, J. A., Kurtides, E. S., and Darsey, J. M.: Coagulation changes in acutely bleeding patients. *Arch. Surg.* 104: 559, 1972.
39. Carvahlo, A. J., Valiancourt, R. A., et al.: Congulation abnormalities in women taken oral contraceptives. *J. A. M. A.* 237: 875, 1977.
40. Caspary, E. A., and Peberdy, M.: Oral contraception and blood platelet ad adhesiveness. *Lancet* 1: 1142, 1965.
41. Cederblad, G., Hahn, L., Korsan-Bengtsen, K., et al.: Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. *Haemostas.* 6: 294, 1977.
42. Conrad, J., Samama, M., and Salomon, Y.: Antithrombin III and the oestrogen content of combined oestro-progestagen contraceptives. *Lancet* 2: 1148, 1972.
43. Coope, J., Thomson, J. M., Poller, L.: Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. *Br. Med. J.* 18: 139, 1975.
44. Dame, W. R., Stahl, K., Themann, H., and Beller, F. K.: Ultrastructural morphometric investigation on human platelets after long-term ingestion of oral contraceptives. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 9: 321, 1979.
45. Daniel, D. G., Bloom, A. L., Giddings, V. C., et al.: Increased factor IX levels in puerperium during administration of diethylstilboestrol. *Br. Med. J.* 1: 80, 1968.
46. Daniel, D. G.: Estrogens and puerperal thromboembolism. *Am. Heart J.* 78: 720, 1969.
47. Das, P. C., Allan, A. G. E., Woodfield, D. G., and Cash, J. D.: Fibrin degradation products in sera of normal subjects. *Br. Med. J.* 4: 718, 1967.
48. Davies, T., McNicol, G. P., Fieldhouse, G., et al.: The effects of therapy with oestriol succinate and ethinyl oestradiol on the haemostatic mechanism in post-menopausal women. *Thromb. Haemostas.* 35: 403, 1976.
49. Davies, T., McNicol, G. P., Fieldhouse, G., et al.: A comparison of the effects of oestriol succinate and ethinyl oestradiol on blood coagulation, platelet function and fibrinolysis in postmenopausal women. *Thromb. Res.* 35: 403, 1976.
50. Damsky, J., and Finkus, G.: Effect of oestrogen on blood clotting factors. *Metabolism* 14: 418, 1965.
51. Dugdale, M., and Masi, A.: Hormonal contraception and thromboembolic disease: effects of the oral contraceptives on hemostatic mechanism. A review of the literature. *J. Clin. Pathol.* 24: 23, 1971.
52. Edwards, R. W., et al.: Kontrazeption gemessen mit vier unterschiedlichen Methoden. In *Gefäßwand und Blutgerinnung*, edited by H. Ludwig and H. J. Genz. Schattauer Verl. Stuttgart, New York, 1981.

53. Egeberg, O., and Owron, P. A.: Oral contraception and blood coagulability. *Br. Med. J.* 1: 220, 1963.
54. Eisenmenger, W. J., Slater, R. J., and Bongiovanni, A. M.: Hypercoagulability of the blood of patients with hepatic cirrhosis following administration of ACTH. *Am. J. Med.* 13: 27, 1952.
55. Esselier, A. F., Jeanneret, R. L., and Schoch, K.: ACTH-Eosinophilentest und Heparin. *Klin. Wochenschr.* 32: 625, 1954.
56. Fagerhol, M. K., and Abildgaard, U.: Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentration. *Scand. J. Haematol.* 1: 10, 1970.
57. Fagerhol, M. K., Abildgaard, U., Beresjö, P., and Jakobson, A.: Oral contraceptives and serum antithrombin III. *Scand. J. Haematol.* 1: 605, 1974.
58. Farbiszewski, R., and Kurowska, T.: Platelet adhesions, aggregation and fibrinolysis after the oral administration after the contraceptive Lyfibrin. *Thromb. Diath. Haemorrh.* 304, 1970.
59. Fearnley, G. R., and Bunim, J. J.: Effect of ACTH on the erythrocyte sedimentation rate and plasma fibrinogen and serum protein levels in normal persons. *Lancet* 15: 1113, 1951.
60. Fisch, J. R., and Freedman, S. H.: Oral contraceptives, ABO-Blood groups and in vitro fibrin formation. *Obstet. Gynecol.* 46: 473, 1975.
61. Fletcher, A. A., Dauphinee, J. A., and Dryzio, M. A.: Plasma fibrinogen and the sedimentation rate in rheumatoid arthritis and their response to the administration of cortisone and adrenocorticotrophic hormone (ACTH). *Clin. Invest.* 31: 561, 1952.
62. Frick, G., Goretzki, G., and Frick, G.: Verhalten der Heparinolyse und der fibrinolytischen Spaltprodukte nach Absetzen hormonaler Kontrazeptiva. *Zentralbl. Gynaekol.* 98: 908, 1976.
63. Gasser, C., and Anders, H.: Cortisol und ACTH bei Thromboembolien. *Schweiz. Med. Wochenschr.* 83: 1036, 1953.
64. Genell, S.: A study of variations in the number of blood platelets during the menstrual cycle. *J. Obstet. Gynaecol. Br. Commonw.* 43: 1124, 1936.
65. Ghezzi, F., Male, A., and Pegoraro, L.: Effects of oestrogen-progestin oral contraceptives on blood coagulation fibrinolysis and platelet aggregation. *Hematologica* 65: 737, 1980.
66. Gjoennaess, H., Munkely, J., Froelich, W., et al.: Effect of estrogen treatment on coagulation and fibrinolysis in postmenopausal women. With special reference to cold activation of factor VII. *Gynecol. Obstet. Invest.* 9: 109, 1978.
67. Gjoennaess, H., Fagerhol, M. K., and Stormorken, H.: Studies on coagulation and fibrinolysis in blood from postmenopausal women with and without oestrogen treatment. *Br. J. Obstet. Gynecol.* 82: 151, 1975.
68. Gjoennaess, H., and Stormorken, H.: Activation of Factor VII in oral contraceptives. *Thromb. Diath. Haemorrh.* 24: 308, 1970.
69. Godlowski, Z. Z.: Prevention of hormonal eosinopenia and lymphopenia by inhibition of clotting in blood. *Br. Med. J.* 2: 654, 1954.
70. Goretzki, G., Frick, G., and Frick, U.: Hormonale Kontrazeption-Thromboembolie und Operationsrisiko. *Zentralbl. Gynaekol.* 98: 600, 1976.
71. Graeff, H., Battis, P., Hafer, R., and Zander, J.: Evaluation of hypercoagulability in users of oral contraceptives. *Klin. Wochenschr.* 55: 175, 1977.
72. Graeff, H., Schütz, H. J., Hugo, R. v., et al.: The effect of endotoxin and "endotoxinoid" infusion in pregnant rabbits. *Arch. Gynaekol.* 216: 215, 1974.
73. Günter, R. G., and Kiefer, E.: Das Verhalten der Blutgerinnungsfaktoren bei der Anwendung von Cortison und Prednison. *Med. Klin.* 39: 1633, 1956.
74. Haefeli, H., Cloeren, St., and Mall, M.: Ovulationshemmer und Emboliegefahr. *Gynecologia* 160: 281, 1965.
75. Halberstadt, E., Römer, E., and Stein, W.: Plättchen Aggregation unter hormonellen Kontrazeptiva. *Thromb. Diath. Haemorrh. (Suppl.)* 49: 147, 1971.
76. Haller, J., König, A., and Poliwoda, H.: Hormonausscheidungen und Blutgerinnungsfaktoren unter oraler Gestagen-Östrogenbehandlung (Beurteilung des Thrombophiesrisikos). *Geburtsh. Frauenheilkde.* 25: 215, 1975.
77. Hamilton, L. H.: Heparin-induced burst of the heparin response to cortisone. *Endocrinologie* 61: 392, 1957.
78. Hathaway, W., and Bonnar, J.: *Perinatal Medicine*. A. Stratton, New York, 1970.
79. Hedlin, A. M.: The effect of oral contraceptives estrogen on blood coagulation and fibrinolysis. *Thromb. Diath. Haemorrh.* 33: 310, 1970.
80. Hedlin, A. M., and Monkhouse, F. C.: Changes in spontaneous fibrinolytic activity during use of oral contraceptives. *Obstet. Gynecol.* 37: 225, 1971.
81. Herbeth, B., Bagrel, A., Dalo, B., et al.: Influence of oral contraceptives of differing dosages on α -1-antitrypsin, α -glutamyltransferase and alkaline phosphatase. *Clin. Chim. Acta* 112: 293, 1981.
82. Hilden, M., Amris, C. J., and Starup, J.: The hemostatic mechanism in oral contraception. *Acta Obstet. Gynecol. Scand.* 46: 562, 1967.
83. Hougie, C., Rutherford, R. N., Banks, A. L., and Coburn, A. W.: Effect on Progesterin-Estrogen oral contraceptive on blood clotting factors. *Metabolism* 14: 411, 1965.
84. Howie, P. W., Evans, K., Forbes, C. D., et al.: The effects of stilbestrol and quinestrol upon coagulation and fibrinolysis. *Br. J. Obstet. Gynaecol.* 75: 1975.
85. Howie, P. W., Mallinson, A. C., Prentice, C. R. M., et al.: Effect of combined oestrogen-progestogen oral contraceptives, oestrogen and progestogen on antipain and antithrombin activity. *Lancet* 2: 1220, 1970.
86. Hunter, D. J. S., Anderson, A. B. M., Hadden, M.: Changes in coagulation factors in postmenopausal women on ethinyl-oestradiol. *Br. J. Obstet. Gynecol.* 86: 488, 1979.
87. Inman, W. H. W., Vessey, M. P., Westerholm, B., and Egeland, A.: Thromboembolic disease and the steroidal content of oral contraceptives. A report to the committee on safety of drugs. *Br. Med. J.* 2: 203, 1970.
88. Jeffcoate, T. N. A., Miller, J., Roos, R. F., Tindall, V. R.: Puerperal thromboembolism in relation to the inhibition of lysis by oestrogen therapy. *Br. Med. J.* 2: 49, 1968.
89. Jolly, D. W., Kadis, B. M., and Nelson, Jr., T. E.: Estrogen and Prothrombin synthesis. The prothrombogenic action of estrogen. *Biochem. Biophys. Res. Commun.* 74: 41, 1977.
90. Jordan, W. M.: Pulmonary embolism. *Lancet* 2: 1146, 1961.
91. Kato, M.: Über die Veränderung der Blutplättchen in den verschiedenen Stadien des menstruellen Cycles. *Zentralbl. Gynaekol.* 57: 1004, 1933.
92. Kaulla, E. v., Droegemüller, W., Aoki, N., and Kaulla, K. N.: Effects of estrogens on post partum hypercoagulability and Antithrombin III activity. *Am. J. Obstet. Gynecol.* 113: 92, 1972.
93. Kaulla, E. v., Droegemüller, W., Aoki, N., and Kaulla, K. N.: Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives. *Am. J. Obstet. Gynecol.* 109: 868, 1971.

95. Kaulla, E. v., Droegemüller, W., and Kaulla, K. N. v.: Conjugated estrogens and hypercoagulability. *Am. J. Obstet. Gynecol.* 122: 688, 1975.
96. Kaulla, E. v., and Kaulla, K. N. v.: Oral contraceptives and low AT III activity. *Lancet* 19: 36, 1970.
97. Köhler, V., Loll, H., and Schröder, H.: Aufhebung des Heparineffektes auf die Blutgerinnung durch ACTH. *Klin. Wochenschr.* 31: 610, 1953.
98. Korsan-Bengsten, K., and Laroche, B.: Effect on blood coagulation and fibrinolysis in woman using norethisterone or a combination of ethinylloestradiol and quingestonol. *Gynecol. Obstet. Invest.* 9: 312, 1978.
99. Kullander, S., Svanhede, I., and Åstedt, R.: Coagulative and fibrinolytic studies on postmenopausal women treated with a new non-steroidal oestrogen. *Acta Obstet. Gynecol. Scand.* 56: 371, 1977.
100. Lähdenmäki, P., Rasi, V., Luukainen, T., and Hyllyä, G.: Coagulation factors in women using oral contraceptive devices immediately after abortion. *Acta Obstet. Gynecol. Scand.* 56: 371, 1977.
101. Langelius, A., Lunell, N. O., and Blombäck, M.: Natural oestrogen in the female climacteric - Influence on blood coagulation and fibrinolysis. *Thromb. Haemostas.* 40: 532, 1978.
102. Laudan, G.: Zur Wirkung von Cortison auf Entzündung und Blutgerinnungsfaktorensystem. *Ärzt. Wochenschr.* 10: 1105, 1955.
103. Laurell, C. B., Kullander, S., and Thorell, J.: Effect of administration of a combined oestrogen-progestin contraceptive on the level of individual plasma proteins. *Scand. J. Clin. Invest.* 21: 337, 1968.
104. Laurell, C. B., Kullander, S., and Thorell, J.: Rate of plasma protein normalisation after Parturition and withdrawal of oral contraceptives. *Scand. J. Clin. Lab. Invest.* 26: 345, 1973.
105. Lechner, K., Hartmann, W. H., Schneider, F., et al.: Beeinflussung von Blutgerinnung und Fibrinolyse durch Östrogen, Gestagen und eine Östrogen-Gestagen-Kombination. *Klin. Wochenschr.* 54: 431, 1976.
106. Leff, B., Henriksen, R. A., and Owen, W. G.: Effect of oral contraceptive use on platelet prothrombin converting (platelet factor 3) activity. *Thromb. Res.* 15: 631, 1979.
107. Lillie, M. A., and Mink, J. B.: Progestational agents and blood coagulation. VI. Relationship of ABO blood types to changes induced by oral contraceptive. *Am. J. Obstet. Gynecol.* 119: 406, 1974.
108. Lira, P., Rivera, L., Diaz, S., and Croxatto, H. B.: Study of blood coagulation in women treated with Megestrol acetate implants. *Contraception* 12: 639, 1975.
109. Lorrain, V., and Harel, P.: Effects of certain contraceptive hormones on blood coagulation. *Fertil. Steril.* 23: 422, 1972.
110. Ludwig, H.: Surface structure of the human term placenta and the uterine wall post partum in the screen scan. *Am. J. Obstet. Gynecol.* 111: 328, 1971.
111. Ludwig, H.: Ovulationshemmer, Haemostase und Gefäßskomplikationen. *Der Gynäkologe* 2: 195, 1970.
112. Ludwig, H.: Hämatologische und hämostaseologische Veränderungen bei der Ovulationshemmung durch Östrogen-Gestagen-Kombination. *Fortschr. Geburtsh. Gynäk.* 21: 198, 1965.
113. Ludwig, H., and Zuber, E.: Klinische und biochemische Resultate bei der Behandlung mit Marvelon - einem neuen steroidal Ovulationshemmer. *Geburtsh. u. Frauenheilk.* 35: 369, 1975.
114. Mammen, E. F.: Oral contraceptives and blood coagulation: A critical review. *Am. J. Obstet. Gynecol.* 112: 701, 1972.
115. Margulis, R. R., Ambrus, J. L., Mink, J. B., and Stryker, J. C.: Progestational agents and blood coagulation. *Am. J. Obstet. Gynecol.* 93: 161, 1965.
116. McEntee, M. P., Jestv, J., and Hultin, M. B.: Effect of oral contraceptives on Antithrombin III. *Thromb. Res.* 24: 13, 1981.
117. McGrath, K. M., and Castaldi, P. A.: Changes in coagulation factors and platelet function in response to progestational agents. *Haemostasis* 4: 65, 1975.
118. McGrath, K. M., and Castaldi, P. A.: Cyclical changes in coagulation factors associated with the use of progestational agents. *Haemostasis* 4: 73, 1975.
119. McKay, D. G.: Hematologic evidence of disseminated intravascular coagulation in eclampsia. *Obstet. Gynecol. Surv.* 27: 399, 1974.
120. McKay, D. G.: *Disseminated Intravascular Coagulation*. Harper & Row, New York, 1965.
121. Meade, T. W., Haines, A. P., North, W. R. S., et al.: Haemostatic, Lipid and blood-pressure profiles of women on oral contraceptives containing 50 µg or 30 µg oestrogen. *Lancet* 1: 948, 1970.
122. Meade, T. W., Greenberg, C., and Thomson, S. C.: Progestational agents and cardiovascular reactions. *Am. J. Obstet. Gynecol.* 111: 1157, 1980.
123. Menczel, J., and Dreyfuss, F.: Effect of prednisone on blood coagulation time in patients on dicumarol therapy. *J. Lab. Clin. Med.* 56: 14, 1960.
124. Menon, S., Pendergast, M., Kannie, G.: Study of blood coagulation activity in normal women, pregnant women on oral contraceptives. *J. Obstet. Gynaecol. Br. Commonw.* 77: 752, 1970.
125. Mettler, L., and Selchow, B. M.: Oral contraceptives and platelet function. *Thromb. Diath. Haemorrh.* 28: 213, 1972.
126. Mettler, L., and Shirwani, D.: The blood count during the ovarian cycle. *Am. J. Obstet. & Gynecol.* 119: 1038, 1974.
127. Miller, K. E., and Pizzo, S. V.: Venous and arterial thromboembolic disease in women using oral contraceptives. *Am. J. Obstet. Gynecol.* 144: 824, 1982.
128. Mink, J. B., Courey, N. G., Moore, R. H., et al.: Progestational agents and blood coagulation IV. Changes induced by progesterone alone. *Am. J. Obstet. Gynecol.* 113: 739, 1972.
129. Mink, J. B., Courey, N. G., Nieswander, K. R., et al.: Progestational agents and blood coagulation V. Changes induced by sequential oral contraceptive therapy. *Am. J. Obstet. Gynecol.* 119: 401, 1974.
130. Möbius, W., and Johannes, S.: Schwankungen der Zahl der Thrombozyten während des weiblichen Genitalzyklus. *Zentralbl. Gynäk.* 85: 489, 1963.
131. Nilsen, P. A., Meling, A. B., and Abildgaard, U.: Study of the suppression of lactation and the influence on blood clotting with bromocriptine (CB 154) (Parlodol): a double blind comparison with diethylstilbestrol. *Acta Obstet. Gynecol. Scand.* 55: 39, 1976.
132. Nilsson, I. M., and Kullander, S.: Coagulation and fibrinolytic studies during continuous use of low dose gestagen. *Acta Endocrinol.* 65: 111, 1970.
133. Nilsson, I. M., and Kullander, S.: Coagulation and fibrinolytic studies during use of gestagens. *Acta Obstet. Gynecol. Scand.* 46: 286, 1967.
134. Nilsson, I. M., Svensson, B., Maydorn, B., et al.: The influence of age, sex and the use of oral contraceptives on the inhibitory effects of endothelial cells and PG-endothelial cells on platelet function. *Scand. J. Haemat.* 21: 177, 1976.
135. Notelovitz, M.: Coagulation, oestrogen and the menopause. *Clin. Obstet. Gynaecol.* 4: 107, 1977.
136. Notelovitz, M., Kitchens, C., Ware, M., et al.: Combination oestrogen and progesterone replacement therapy does not adversely affect coagulation. *Obstet. Gynecol.* 62: 596, 1983.

- ent competition of a controversial issue. *Acta Obstet. Gynecol. Scand. (Suppl.)* 64: 13, 1976. *Scand. J. Obstet. Gynecol.* 64: 13, 1976.
184. Zaha, I. J., Dreyfuss, F., Kalef, M., and Soferman, N.: Adenosine diphosphate-induced platelet aggregation in healthy women with and without a combined and a sequential pill. *Am. J. Obstet. Gynecol.* 117: 107, 1979.
 185. Zahavi, J., Dreyfuss, F., Kalef, M., et al.: Adenosine diphosphate-induced platelet aggregation in healthy women with and without a combined and sequential contraceptive pill. *Am. J. Obstet. Gynecol.* 117: 107, 1973.
 186. Adenosine, diphosphate-induced platelet aggregation of depressed ATIII activity associated with oral contraceptives. *Surg. Gynecol. Obstet.* 133: 609, 1971.